These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.

Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAB in their systems.

MaxCyte (NASDAQ:MXCT – Free Report) had its price objective cut by Stifel Nicolaus from $11.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on ...

Investment analysts at William Blair issued their Q1 2026 earnings estimates for MaxCyte in a report released on Wednesday, March 12th. William Blair analyst M. Larew expects that the company will ...

A novel acoustofluidics method enhances intracellular nanoparticle delivery, improving biophysical research and therapeutic ...

Q4 2024 Earnings Call Transcript March 12, 2025 Harvard Bioscience, Inc. beats earnings expectations. Reported EPS is $0.06, ...

A recent study published in Engineering presents an innovative acoustofluidics-based approach for intracellular nanoparticle ...

Q4 2024 Earnings Call Transcript March 11, 2025 MaxCyte, Inc. beats earnings expectations. Reported EPS is $-0.1004, ...

Factors such as increase in the prevalence of cancer, rise in demand for minimally invasive treatments, and government initiatives & reimbursement policies drive the growth of the tumor ablation ...

Now in its third year, the trial is led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and clinical investigators at the University of Pennsylvania. It is funded by the Coronavirus ...

CRISPR libraries enable scientists to systematically investigate gene functions, identify novel drug targets, and develop personalized therapies.